RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) (“Talecris” or the “Company”) today announced that it has commenced an offering through a private placement of $550 million aggregate principal amount of senior notes due 2016 (the “Notes”). Talecris intends to use the proceeds from the offering to repay its First and Second Lien Term Loans, repay a portion of borrowings under its Revolving Credit Facility, and to pay related fees and expenses.
